A cerebrospinal fluid substudy includes a 2-year follow-up and 2 additional doses of 600-mg ocrelizumab at weeks 48 and 72. The estimated completion date is December 29, 2025. Ublituximab ...
That could give the drugs an advantage over CD20-targeting therapies like Roche's Ocrevus (ocrelizumab) that inhibit B cells across the board, leaving patients prone to infections and other side ...
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback